About one in five U.S. children who develop pediatric Acute Respiratory Distress Syndrome (ARDS) dies each year. There are no known medications that benefit most patients with this condition. Clinicians provide primarily supportive care, such as ventilator management, sedation, nutrition, and fluid management.
One therapy in use is effective for some patients but not others. Now, a research team seeks to improve the ability of clinicians to identify which children could benefit from this therapy as well as which children are at greater risk of dying from ARDS.
“Our eventual goal is to find therapies that improve mortality for kids with this severe condition,” said Anoopindar Bhalla, M.D., Associate Professor of Clinical Pediatrics at the Keck School of Medicine of the University of Southern California…
Read the full article here.
